Related Experiment Videos
XRCC1-DNA polymerase beta interaction is required for efficient base excision repair
Irina I Dianova1, Kate M Sleeth, Sarah L Allinson
1Radiation and Genome Stability Unit, Medical Research Council, Harwell, Oxfordshire OX11 0RD, UK.
Nucleic Acids Research
|May 14, 2004
Summary
The interaction between X-ray repair cross-complementing protein-1 (XRCC1) and DNA polymerase beta (Pol beta) is crucial for efficient base excision repair (BER) and cellular resistance to DNA damage.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- X-ray repair cross-complementing protein-1 (XRCC1) is vital for DNA base excision repair (BER).
- XRCC1 interacts with DNA ligase IIIalpha, DNA polymerase beta (Pol beta), and other BER proteins.
- XRCC1-deficient cells exhibit sensitivity to DNA damaging agents and delayed DNA base lesion processing.
Purpose of the Study:
- To investigate the functional significance of the XRCC1-Pol beta interaction in BER.
- To assess the impact of disrupted XRCC1-Pol beta interaction on DNA repair efficiency and cellular resistance.
Main Methods:
- Reconstitution of BER reactions using purified human proteins with wild-type and mutant XRCC1-DNA ligase IIIalpha heterodimers.
- Site-directed mutagenesis of XRCC1 to disrupt its interaction with Pol beta.
- Complementation assays in XRCC1-deficient cells using plasmids encoding wild-type or mutant XRCC1.
Main Results:
- A mutation disrupting XRCC1-Pol beta interaction impaired the ligation efficiency of the XRCC1-DNA ligase IIIalpha heterodimer in reconstituted BER.
- XRCC1 protein unable to interact with Pol beta showed reduced ability to rescue hydrogen peroxide sensitivity in XRCC1-deficient cells.
- Disruption of XRCC1-Pol beta interaction negatively impacted overall base excision repair efficiency.
Conclusions:
- The interaction between XRCC1 and Pol beta plays a critical role in coordinating the BER pathway.
- This interaction is essential for maintaining cellular genomic stability and resistance to DNA damaging agents.
- Targeting the XRCC1-Pol beta interaction could be a strategy for enhancing cancer therapy.